首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >N-1-tert-butyl-substituted quinolones: in vitro anti-Mycobacterium avium activities and structure-activity relationship studies.
【2h】

N-1-tert-butyl-substituted quinolones: in vitro anti-Mycobacterium avium activities and structure-activity relationship studies.

机译:N-1-叔丁基取代的喹诺酮类药物:体外抗鸟分枝杆菌活性和构效关系的研究。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We determined the MICs of 63 quinolones against 14 selected reference and clinical strains of the Mycobacterium avium-Mycobacterium intracellulare complex. Sixty-one of the compounds were selected from the quinolone library at Parke-Davis, Ann Arbor, Mich., including N-1-tert-butyl-substituted agents. T 3761 and tosufloxacin were also tested. The activities of all 63 compounds were compared with those of ciprofloxacin and sparfloxacin. The results showed 45 of the quinolones to be active against the M. avium-M. intracellulare complex, with MICs at which 50% of the strains were inhibited (MIC50s) of less than 32 micrograms/ml. Twenty-four of these quinolones had activities equivalent to or greater than that of ciprofloxacin, and nine of them had activities equivalent to or greater than that of sparfloxacin. The most active compounds were the N-1-tert-butyl-substituted quinolones, PD 161315 and PD 161314, with MIC50s of 0.25 microgram/ml and MIC90s of 1 microgram/ml; comparable values for ciprofloxacin were 2 and 4 micrograms/ml, respectively, while for sparfloxacin they were 1 and 2 micrograms/ml, respectively. The next most active compounds, with MIC50s of 0.5 microgram/ml and MIC90s of 1 microgram/ml, were the N-1-cyclopropyl-substituted quinolones, PD 138926 and PD 158804. These values show that the tert-butyl substituent is at least as good as cyclopropyl in rendering high levels of antimycobacterial activity. However, none of the quinolones showed activity against ciprofloxacin-resistant laboratory-derived M. avium-M. intracellulare complex strains. A MULTICASE program-based structure-activity relationship analysis of the inhibitory activities of these 63 quinolones and 109 quinolones previously studied against the most resistant clinical strain of M. avium was also performed and led to the identification of two major biophores and two biophobes.
机译:我们确定了63喹诺酮类药物的MIC对14个选定的参考菌株和鸟分枝杆菌-分枝杆菌细胞内复合物的临床菌株。六十一种化​​合物选自位于密西根州安阿伯市的Parke-Davis的喹诺酮文库,包括N-1-叔丁基取代的试剂。还测试了T 3761和tosufloxacin。将所有63种化合物的活性与环丙沙星和司帕沙星进行了比较。结果显示45种喹诺酮类药物对鸟分枝杆菌有活性。细胞内复合物,其中抑制50%菌株的MIC(MIC50)低于32微克/毫升。这些喹诺酮中有二十四种具有等于或大于环丙沙星的活性,其中九种具有等于或大于斯巴沙星的活性。活性最高的化合物是N-1-叔丁基取代的喹诺酮,PD 161315和PD 161314,MIC50为0.25微克/毫升,MIC90为1微克/毫升。环丙沙星的可比值分别为2和4微克/毫升,而司帕沙星的可比值分别为1和2微克/毫升。 MIC50为0.5微克/毫升和MIC90为1微克/毫升的第二高活性化合物是N-1-环丙基取代的喹诺酮,PD 138926和PD158804。这些值表明,叔丁基取代基至少为在提供高水平的抗分枝杆菌活性方面与环丙基一样好。但是,没有一种喹诺酮类药物具有抗环丙沙星实验室衍生的鸟分枝杆菌-M的活性。细胞内复杂菌株。基于MULTICASE程序的先前对这63种喹诺酮类药物和109种喹诺酮类药物对鸟抗支原体的最耐药临床菌株的抑制活性的基于结构-活性关系的分析,还导致了两个主要生物体和两个生物体的鉴定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号